AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
INITIAL CLINICAL-EXPERIENCE WITH I-131 HUMANIZED LL2 (I-131-HLL2) ANTI-CD22 MAB AGAINST B-CELL MALIGNANCIES
Authors: JUWEID M BHATNAGAR A SHARKEY RM STADMAUER E LUGER S BURTON J STEIN R ALAVI A GOLDENBERG DM
Citation: M. Juweid et al., INITIAL CLINICAL-EXPERIENCE WITH I-131 HUMANIZED LL2 (I-131-HLL2) ANTI-CD22 MAB AGAINST B-CELL MALIGNANCIES, The Journal of nuclear medicine, 39(5), 1998, pp. 273-273
PATIENT-SPECIFIC (PS) ESTIMATES OF RED MARROW DOSE RESULT IN IMPROVEDCORRELATION WITH MYELOTOXICITY
Authors: DUNN RM JUWEID M SHARKEY RM GOLDENBERG DM
Citation: Rm. Dunn et al., PATIENT-SPECIFIC (PS) ESTIMATES OF RED MARROW DOSE RESULT IN IMPROVEDCORRELATION WITH MYELOTOXICITY, The Journal of nuclear medicine, 39(5), 1998, pp. 440-440
PHARMACOKINETICS, DOSIMETRY AND TOXICITY OF RHENIUM-188-LABELED ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODY, MN-14, IN GASTROINTESTINAL CANCER
Authors: JUWEID M SHARKEY RM SWAYNE LC GRIFFITHS GL DUNN R GOLDENBERG DM
Citation: M. Juweid et al., PHARMACOKINETICS, DOSIMETRY AND TOXICITY OF RHENIUM-188-LABELED ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODY, MN-14, IN GASTROINTESTINAL CANCER, The Journal of nuclear medicine, 39(1), 1998, pp. 34-42
PHASE-I HIGH-DOSE TRIAL OF I-13 I-LABELED MN-14 F(AB)(2) ANTI-CEA MABCOMBINED WITH AUTOLOGOUS BONE-MARROW SUPPORT IN PATIENTS (PTS) WITH ADVANCED MEDULLARY-THYROID CANCER (MTC)
Authors: JUWEID M SHARKEY RM SWAYNE LC ALEXANDER S DUNN R RUBIN A HERSKOVIC T GOLDENBERG DM
Citation: M. Juweid et al., PHASE-I HIGH-DOSE TRIAL OF I-13 I-LABELED MN-14 F(AB)(2) ANTI-CEA MABCOMBINED WITH AUTOLOGOUS BONE-MARROW SUPPORT IN PATIENTS (PTS) WITH ADVANCED MEDULLARY-THYROID CANCER (MTC), The Journal of nuclear medicine, 38(5), 1997, pp. 168-168
PREDICTION OF MYELOTOXICITY AFTER RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODIES IN PATIENTS WITHCOLORECTAL CANCERS
Authors: JUWEID M ZHANG CH BLUMENTHAL RD SHARKEY RM DUNLOP D DUNN R GOLDENBERG DM
Citation: M. Juweid et al., PREDICTION OF MYELOTOXICITY AFTER RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODIES IN PATIENTS WITHCOLORECTAL CANCERS, The Journal of nuclear medicine, 38(5), 1997, pp. 970-970
IMPROVED SELECTION OF PATIENTS FOR REOPERATION AFTER PRIMARY SURGERY FOR MEDULLARY-THYROID CARCINOMA (MTC) USING RADIOLABELED ANTI-CEA ANTIBODIES
Authors: JUWEID M SHARKEY RM SWAYNE LC GOLDENBERG DM
Citation: M. Juweid et al., IMPROVED SELECTION OF PATIENTS FOR REOPERATION AFTER PRIMARY SURGERY FOR MEDULLARY-THYROID CARCINOMA (MTC) USING RADIOLABELED ANTI-CEA ANTIBODIES, The Journal of nuclear medicine, 38(5), 1997, pp. 984-984
PHASE-I DOSE-ESCALATION TRIAL OF I-131-LABELED MN-14 F(AB)(2) ANTI-CEA MAB IN PATIENTS WITH MEDULLARY-THYROID CANCER (MTC)
Authors: JUWEID M SHARKEY RM SWAYNE LC PETRYK L DUNN R RUBIN A HERSKOVIC T GOLDENBERG DM
Citation: M. Juweid et al., PHASE-I DOSE-ESCALATION TRIAL OF I-131-LABELED MN-14 F(AB)(2) ANTI-CEA MAB IN PATIENTS WITH MEDULLARY-THYROID CANCER (MTC), The Journal of nuclear medicine, 38(5), 1997, pp. 1115-1115
AN EXPERIMENTAL-MODEL OF RADIOIMMUNOTHERAPY OF MEDULLARY-THYROID CARCINOMA (MTC) WITH RADIOLABELED ANTI-CEA MABS
Authors: JUWEID M STEIN R GOLDENBERG DM
Citation: M. Juweid et al., AN EXPERIMENTAL-MODEL OF RADIOIMMUNOTHERAPY OF MEDULLARY-THYROID CARCINOMA (MTC) WITH RADIOLABELED ANTI-CEA MABS, The Journal of nuclear medicine, 38(5), 1997, pp. 1126-1126
REGRESSION OF ADVANCED REFRACTORY OVARIAN-CANCER TREATED WITH IODINE-131-LABELED ANTI-CEA MONOCLONAL-ANTIBODY
Authors: JUWEID M SHARKEY RM ALAVI A SWAYNE LC HERSKOVIC T HANLEY D RUBIN AD PEREIRA M GOLDENBERG DM
Citation: M. Juweid et al., REGRESSION OF ADVANCED REFRACTORY OVARIAN-CANCER TREATED WITH IODINE-131-LABELED ANTI-CEA MONOCLONAL-ANTIBODY, The Journal of nuclear medicine, 38(2), 1997, pp. 257-260
TC-99(M)-LL1 - A POTENTIAL NEW BONE-MARROW IMAGING AGENT
Authors: JUWEID M DUNN RM SHARKEY RM RUBIN AD HANSEN HJ GOLDENBERG DM
Citation: M. Juweid et al., TC-99(M)-LL1 - A POTENTIAL NEW BONE-MARROW IMAGING AGENT, Nuclear medicine communications, 18(2), 1997, pp. 142-148
PROSPECTS OF RADIOIMMUNOTHERAPY IN EPITHELIAL OVARIAN-CANCER - RESULTS WITH IODINE-131-LABELED MURINE AND HUMANIZED MN-14 ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODIES
Authors: JUWEID M SWAYNE LC SHARKEY RM DUNN R RUBIN AD HERSKOVIC T GOLDENBERG DM
Citation: M. Juweid et al., PROSPECTS OF RADIOIMMUNOTHERAPY IN EPITHELIAL OVARIAN-CANCER - RESULTS WITH IODINE-131-LABELED MURINE AND HUMANIZED MN-14 ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODIES, Gynecologic oncology, 67(3), 1997, pp. 259-271
IMPROVED SELECTION OF PATIENTS FOR REOPERATION FOR MEDULLARY-THYROID CANCER BY IMAGING WITH RADIOLABELED ANTICARCINOEMBRYONIC ANTIGEN ANTIBODIES
Authors: JUWEID M SHARKEY RM SWAYNE LC GOLDENBERG DM
Citation: M. Juweid et al., IMPROVED SELECTION OF PATIENTS FOR REOPERATION FOR MEDULLARY-THYROID CANCER BY IMAGING WITH RADIOLABELED ANTICARCINOEMBRYONIC ANTIGEN ANTIBODIES, Surgery, 122(6), 1997, pp. 1156-1165
DEFINING THE OPTIMAL SPACING BETWEEN REPEAT RADIOANTIBODY DOSES IN EXPERIMENTAL-MODELS - IS THERE AN ACCURATE MEASUREMENT FOR HEMATOPOIETICRECOVERY
Authors: BLUMENTHAL RD ALISAUSKAS R JUWEID M SHARKEY RM GOLDENBERG DM
Citation: Rd. Blumenthal et al., DEFINING THE OPTIMAL SPACING BETWEEN REPEAT RADIOANTIBODY DOSES IN EXPERIMENTAL-MODELS - IS THERE AN ACCURATE MEASUREMENT FOR HEMATOPOIETICRECOVERY, Cancer, 80(12), 1997, pp. 2624-2635
CAN OCCULT METASTASES BE TREATED BY RADIOIMMUNOTHERAPY
Authors: DUNN RM JUWEID M SHARKEY RM BEHR TM GOLDENBERG DM
Citation: Rm. Dunn et al., CAN OCCULT METASTASES BE TREATED BY RADIOIMMUNOTHERAPY, Cancer, 80(12), 1997, pp. 2656-2659
MAB LL1 REACTS WITH THE CELL-SURFACE INVARIANT CHAIN OF HLA-DR COMPLEXES ON PLASMA-MEMBRANES - IN-VITRO AND IN-VIVO RESULTS
Authors: HANSEN HJ GOLDENBERG DM SHARKEY RM JUWEID M MATTES MJ
Citation: Hj. Hansen et al., MAB LL1 REACTS WITH THE CELL-SURFACE INVARIANT CHAIN OF HLA-DR COMPLEXES ON PLASMA-MEMBRANES - IN-VITRO AND IN-VIVO RESULTS, The FASEB journal, 10(6), 1996, pp. 1222-1222
IMPROVED DETECTION OF MEDULLARY-THYROID CANCER WITH RADIOLABELED ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN
Authors: JUWEID M SHARKEY RM BEHR T SWAYNE LC RUBIN AD HERSKOVIC T HANLEY D MARKOWITZ A DUNN R SIEGEL J KAMAL T GOLDENBERG DM
Citation: M. Juweid et al., IMPROVED DETECTION OF MEDULLARY-THYROID CANCER WITH RADIOLABELED ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN, Journal of clinical oncology, 14(4), 1996, pp. 1209-1217
RADIOIMMUNOTHERAPY OF MEDULLARY-THYROID CANCER WITH IODINE-131-LABELED ANTI-CEA ANTIBODIES
Authors: JUWEID M SHARKEY RM BEHR T SWAYNE LC HERSKOVIC T PEREIRA M RUBIN AD HANLEY D DUNN R SIEGEL J GOLDENBERG DM
Citation: M. Juweid et al., RADIOIMMUNOTHERAPY OF MEDULLARY-THYROID CANCER WITH IODINE-131-LABELED ANTI-CEA ANTIBODIES, The Journal of nuclear medicine, 37(6), 1996, pp. 905-911
IMPROVED DETECTION OF MEDULLARY-THYROID CANCER WITH RADIOLABELED ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN
Authors: JUWEID M SHARKEY RM BEHR TM SWAYNE LC RUBIN AD HERSKOVIC T HANLEY D MARKOWITZ AL DUNN R SIEGEL J KAMAL T GOLDENBERG DM
Citation: M. Juweid et al., IMPROVED DETECTION OF MEDULLARY-THYROID CANCER WITH RADIOLABELED ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN, The Journal of nuclear medicine, 37(5), 1996, pp. 24-24
FACTORS AFFECTING THE RELATIONSHIP BETWEEN THE RED MARROW DOSE AND MYELOTOXICITY IN PATIENTS RECEIVING RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTI-CEA MONOCLONAL-ANTIBODIES
Authors: JUWEID M BEHR TM SHARKEY RM DUNN R RUBIN AD GOLDENBERG DM
Citation: M. Juweid et al., FACTORS AFFECTING THE RELATIONSHIP BETWEEN THE RED MARROW DOSE AND MYELOTOXICITY IN PATIENTS RECEIVING RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTI-CEA MONOCLONAL-ANTIBODIES, The Journal of nuclear medicine, 37(5), 1996, pp. 164-164
DOSIMETRIC POTENTIAL OF MINIMAL RESIDUAL DISEASE USING RADIOLABELED ANTIBODIES
Authors: DUNN RM JUWEID M BEHR TM SIEGEL JA SHARKEY RM GOLDENBERG DM
Citation: Rm. Dunn et al., DOSIMETRIC POTENTIAL OF MINIMAL RESIDUAL DISEASE USING RADIOLABELED ANTIBODIES, The Journal of nuclear medicine, 37(5), 1996, pp. 167-167
RADIOIMMUNOTHERAPY IN PATIENTS WITH CEA-PRODUCING CANCERS AND SMALL-VOLUME DISEASE USING I-131-LABELED ANTI-CEA MONOCLONAL-ANTIBODY NP-4 F(AB')(2)
Authors: JUWEID M SHARKEY RM SWAYNE LC BEHR TM DUNN R GOLDENBERG DM
Citation: M. Juweid et al., RADIOIMMUNOTHERAPY IN PATIENTS WITH CEA-PRODUCING CANCERS AND SMALL-VOLUME DISEASE USING I-131-LABELED ANTI-CEA MONOCLONAL-ANTIBODY NP-4 F(AB')(2), The Journal of nuclear medicine, 37(5), 1996, pp. 735-735
RADIOIMMUNOTHERAPY OF ADVANCED REFRACTORY OVARIAN-CANCER WITH I-131-LABELED MN-14 IGG ANTI-CEA MAB - AN ONGOING PHASE-I STUDY
Authors: JUWEID M SHARKEY RM BEHR TM SWAYNE LC DUNN R RUBIN A HERSKOVIC T HANLEY D GOLDENBERG DM
Citation: M. Juweid et al., RADIOIMMUNOTHERAPY OF ADVANCED REFRACTORY OVARIAN-CANCER WITH I-131-LABELED MN-14 IGG ANTI-CEA MAB - AN ONGOING PHASE-I STUDY, The Journal of nuclear medicine, 37(5), 1996, pp. 736-736
CLINICAL-EVALUATION OF TUMOR TARGETING WITH THE ANTICARCINOEMBRYONIC ANTIGEN (CEA) MURINE MN-14 F(AB)(2) AS A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY
Authors: JUWEID M SHARKEY RM BEHR TM MARKOWITZ AL SWAYNE LC DUNN R RUBIN A HERSKOVIC T HANLEY D GOLDENBERG DM
Citation: M. Juweid et al., CLINICAL-EVALUATION OF TUMOR TARGETING WITH THE ANTICARCINOEMBRYONIC ANTIGEN (CEA) MURINE MN-14 F(AB)(2) AS A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY, The Journal of nuclear medicine, 37(5), 1996, pp. 738-738
REGIONAL RADIOACTIVITY QUANTITATION BASED ON SPECT
Authors: DUNN RM JUWEID M BEHR TM SIEGEL JA SHARKEY RM GOLDENBERG DM
Citation: Rm. Dunn et al., REGIONAL RADIOACTIVITY QUANTITATION BASED ON SPECT, The Journal of nuclear medicine, 37(5), 1996, pp. 1048-1048
TC-99M-LL1 - A POTENTIALLY NEW BONE-MARROW IMAGING AGENT
Authors: JUWEID M SHARKEY RM DUNN R HANLEY D HERSKOVIC T RUBIN A HANSEN HJ GOLDENBERG DM
Citation: M. Juweid et al., TC-99M-LL1 - A POTENTIALLY NEW BONE-MARROW IMAGING AGENT, The Journal of nuclear medicine, 37(5), 1996, pp. 1073-1073
Risultati: 1-25 | 26-36